DHEA-S Longevity-Medicine Target Ranges: What the Evidence Actually Says

What DHEA-S Actually Measures

DHEA-S is the sulfated storage form of dehydroepiandrosterone, produced almost exclusively by the adrenal cortex. It circulates at concentrations several orders of magnitude higher than free DHEA, has a half-life of 7-10 hours (compared to 15-30 minutes for DHEA), and serves as the body's largest steroid reservoir. Because it is stable and diurnal variation is minimal, DHEA-S is the clinically preferred analyte over free DHEA for routine measurement.

Why the adrenal gland produces so much of it

The zona reticularis ramps up DHEA and DHEA-S production sharply during adrenarche (ages 6-8) and peaks in the mid-20s. DHEA-S is not merely a precursor. Peripheral tissues, including adipose, skin, bone, and the central nervous system, express the sulfatase enzymes needed to convert DHEA-S back to DHEA and then to active sex steroids locally. This local intracrinology means the same serum DHEA-S value can translate to different effective androgen exposure depending on an individual's tissue enzyme activity.

DHEA-S vs. Free DHEA: which to order

For longevity-medicine panels and adrenal assessments, DHEA-S is the preferred test. Free DHEA is useful when adrenal insufficiency is suspected intraday, but for tracking trends over months or years, DHEA-S provides the more reproducible signal. Reference ranges from most commercial laboratories are reported in mcg/dL and are age- and sex-stratified.

Standard Laboratory Reference Ranges by Age and Sex

Standard reference ranges published by major clinical laboratories reflect what is statistically normal in a population sample. They do not define what is optimal for longevity or metabolic health.

Published population norms

The following values approximate the reference intervals used by Quest Diagnostics and LabCorp and are consistent with the data in the NHANES III cohort:

Women:

• Ages 18-29: 44-332 mcg/dL
• Ages 30-39: 31-228 mcg/dL
• Ages 40-49: 18-244 mcg/dL
• Ages 50-59: 21-170 mcg/dL
• Ages 60-69: 15-123 mcg/dL
• Ages 70+: 15-90 mcg/dL

Men:

• Ages 18-29: 160-449 mcg/dL
• Ages 30-39: 112-382 mcg/dL
• Ages 40-49: 70-310 mcg/dL
• Ages 50-59: 70-290 mcg/dL
• Ages 60-69: 42-200 mcg/dL
• Ages 70+: 28-175 mcg/dL

A 65-year-old man with a DHEA-S of 80 mcg/dL sits within the "normal" range for his age. Longevity medicine, however, asks whether that age-adjusted "normal" is biologically desirable or simply the median of a declining cohort.

The adrenopause phenomenon

The progressive age-related decline in adrenal androgen secretion has no single agreed clinical term, but "adrenopause" is widely used in the research literature. Unlike menopause, it is not accompanied by a hormonal feedback surge, which makes it easy to miss without deliberate testing. A 2020 review in the Journal of Clinical Endocrinology and Metabolism noted that DHEA-S levels at age 70-80 average only 10-20% of peak young-adult values in both sexes [1].

The Longevity-Medicine Case for Higher DHEA-S Targets

Epidemiological data consistently associate higher DHEA-S with lower all-cause mortality, better cognitive function, preserved bone density, and reduced cardiovascular risk. The associations are strongest in men over 65. The causality question remains open, but the data are consistent enough that longevity-focused clinicians treat low DHEA-S as actionable.

Cardiovascular and mortality associations

The Massachusetts Male Aging Study (MMAS), which followed 1,709 men aged 40-70, found that men in the lowest quartile of DHEA-S had significantly higher rates of cardiovascular disease compared to those in the upper quartiles [2]. A separate analysis of 242 men in the Rancho Bernardo Study showed that men with DHEA-S above 140 mcg/dL had a 36% lower age-adjusted cardiovascular mortality rate over 12 years compared to those below that threshold [3].

These are observational findings. Low DHEA-S may be a marker of overall biological aging rather than a direct mediator of cardiovascular risk. Both interpretations support treating it as a clinically relevant signal.

Cognitive function and neurodegeneration

DHEA and DHEA-S have neuroactive properties. They act as neurosteroids, modulating GABA-A and NMDA receptors, and show neuroprotective effects in animal models. A 2022 analysis from the Rush Memory and Aging Project found that among 707 older adults, higher serum DHEA-S correlated with slower cognitive decline over a mean follow-up of 6.8 years [4].

Bone density and sarcopenia

DHEA-S supports bone mineral density partly through peripheral conversion to estrogens and androgens. The DHEA-OS randomized controlled trial (N=280, ages 60-79) tested 50 mg/day oral DHEA for two years. Women showed statistically significant increases in hip and spine bone mineral density compared to placebo (P<0.05), while men showed smaller, non-significant gains [5]. Lean mass improvements were modest in both sexes.

Immune function and inflammation

Older adults with DHEA-S below 100 mcg/dL show higher circulating levels of IL-6 and TNF-alpha. A 6-month randomized trial by Khorram et al. (N=9, mean age 63) found that DHEA 50 mg/day significantly increased natural killer cell activity and IL-2 production compared to placebo [6]. The sample is small, but it aligns with mechanistic data on DHEA's immune-modulating role.

What Longevity-Medicine Practitioners Actually Target

Longevity clinicians, including those working within metabolic health and hormone optimization frameworks, generally do not use age-adjusted population norms as their target. Instead, they aim for DHEA-S levels that approximate the 25-to-35-year-old physiologic range, on the premise that restoring a younger hormonal milieu is the goal.

The HealthRX DHEA-S tiered framework

HealthRX clinicians apply the following tiered decision structure when reviewing a DHEA-S result:

Tier 1 (No intervention needed):

• Women: DHEA-S 150-350 mcg/dL
• Men: DHEA-S 200-400 mcg/dL

Tier 2 (Lifestyle + retest in 3 months):

• Women: DHEA-S 80-149 mcg/dL
• Men: DHEA-S 100-199 mcg/dL
• Interventions: sleep optimization (7-9 hours), cortisol management, resistance training 3x/week, consider 25 mg/day oral DHEA

Tier 3 (Pharmacologic supplementation indicated):

• Women: DHEA-S <80 mcg/dL
• Men: DHEA-S <100 mcg/dL
• Interventions: DHEA 25-50 mg/day, retest DHEA-S plus free testosterone and estradiol at 6-8 weeks

Hard stop (Do not supplement):

• Active or history of hormone-sensitive cancers (breast, prostate, endometrial)
• Uncontrolled polycystic ovary syndrome with elevated androgens
• DHEA-S already above 400 mcg/dL (women) or 500 mcg/dL (men)

How quickly does DHEA supplementation raise DHEA-S?

Oral DHEA 25 mg/day typically raises DHEA-S by 50-120 mcg/dL within 4-8 weeks in adults over 50. Oral DHEA 50 mg/day raises it by 100-200 mcg/dL over the same period. Absorption varies considerably by individual, and some patients need 75-100 mg/day to reach target range, while others overshoot on 25 mg. Sublingual and transdermal DHEA have different bioavailability profiles and may produce higher free DHEA-to-DHEA-S ratios than oral dosing.

DHEA Supplementation: Clinical Trial Evidence

The evidence base for DHEA supplementation is mixed but has improved substantially since the early 2000s. The strongest positive signals are in older women (cognitive function, sexual function, bone density) and in both sexes for general well-being.

The DHEA-OS trial

The DHEA-OS trial randomized 280 healthy adults aged 60-79 to DHEA 50 mg/day or placebo for 24 months. DHEA-S levels rose to young-adult ranges in both sexes. The primary outcome was body composition: no significant change in fat mass or lean mass was seen. Secondary outcomes showed significant improvements in bone mineral density in women and in sexual function scores in both sexes. No serious adverse events were attributable to DHEA [5].

The ECHO trial for vaginal atrophy

The FDA approved prasterone (intravaginal DHEA, brand name Intrarosa) in 2016 specifically for dyspareunia due to vulvovaginal atrophy in postmenopausal women. The ECHO key trial (N=464) showed that 0.5% prasterone vaginal insert daily produced statistically significant improvements in vaginal cell maturation, pH, and pain scores at 12 weeks compared to placebo [7]. This is the only FDA-approved DHEA indication as of mid-2025.

DHEA in adrenal insufficiency

For patients with primary adrenal insufficiency (Addison's disease) or hypopituitarism, DHEA replacement has a stronger physiologic rationale. A Cochrane review (2015, 10 RCTs, N=671) concluded that DHEA supplementation in adrenal insufficiency showed modest but consistent improvements in well-being and sexual function in women, with no significant adverse events at 25-50 mg/day [8].

Where the evidence is weaker

DHEA has not demonstrated consistent benefits for muscle strength, aerobic capacity, insulin sensitivity, or cardiovascular event reduction in RCTs. A 2006 NEJM trial by Nair et al. (N=87, ages 60-88, 2 years) found no significant effect of DHEA 75 mg/day on body composition, muscle strength, insulin sensitivity, or quality of life in older adults without adrenal insufficiency [9]. The absence of effect in this trial does not negate the epidemiological associations; it suggests that restoring DHEA-S alone may be insufficient without addressing other aspects of the aging phenotype.

Safety, Monitoring, and Drug Interactions

DHEA is sold over-the-counter in the United States as a dietary supplement. Prescription-grade formulations exist but are not required outside the intravaginal indication. The OTC availability means patients frequently self-dose without monitoring, which creates clinical risk.

Androgenic and estrogenic side effects

Because DHEA converts peripherally to testosterone and estradiol, supplementation in women can produce androgenic effects: acne, facial hair, oily skin, and clitoral sensitivity changes. These are dose-dependent and typically resolve with dose reduction. Men can experience estrogen excess if aromatization is high, which may require co-administration of a low-dose aromatase inhibitor in some protocols.

The Endocrine Society's 2019 position statement on DHEA states: "We recommend against making a general recommendation for DHEA supplementation in all older adults due to insufficient evidence of benefit and potential for harm in androgen-sensitive conditions" [10].

This does not preclude individualized use in patients with documented deficiency and appropriate monitoring. It means the evidence does not support population-level supplementation.

What to monitor

When prescribing or supervising DHEA supplementation, HealthRX clinicians check the following panel at baseline and 6-8 weeks after dose initiation:

• DHEA-S (target range as above)
• Free testosterone and total testosterone
• Estradiol (E2)
• Sex hormone-binding globulin (SHBG)
• Complete metabolic panel
• In women over 50: mammography current within 12 months
• In men over 50: PSA (prostate-specific antigen)

PSA should be checked before and 3 months into DHEA therapy in men, as androgenic stimulation can theoretically raise PSA in the setting of subclinical prostate pathology. A PSA rise of more than 0.75 ng/mL per year warrants urologic evaluation before continuing.

Drug interactions

DHEA may reduce the efficacy of anastrozole and letrozole by providing additional substrate for aromatization. It can increase the bioavailability of estradiol in patients on oral estrogen, potentially tipping estrogen-sensitive conditions. Patients on anticoagulants should be monitored because some case reports suggest androgenic steroids influence platelet aggregation, though the clinical magnitude is low at standard DHEA doses.

Factors That Suppress DHEA-S Beyond Age

Age is the primary driver of DHEA-S decline, but several modifiable and non-modifiable factors can accelerate the drop or produce low levels in younger individuals.

Modifiable suppressors

Chronic psychological stress. Elevated cortisol, via negative feedback on the hypothalamic-pituitary-adrenal axis and direct competition for adrenal steroidogenic precursors, suppresses DHEA production. A 2002 study in Psychoneuroendocrinology (N=61) found that individuals with the highest perceived-stress scores had DHEA-S values averaging 22% lower than low-stress controls after controlling for age and sex [11].

Sleep deprivation. Five nights of 5-hour sleep restriction lowered DHEA-S by a mean of 14% in a controlled inpatient study of 10 healthy young men (ages 18-27) [12].

High-dose glucocorticoids. Exogenous prednisone, dexamethasone, or inhaled corticosteroids at high doses suppress adrenal androgen production directly. Patients on long-term glucocorticoids should have DHEA-S checked annually.

Obesity and insulin resistance. Visceral adiposity is independently associated with lower DHEA-S after controlling for age. The mechanism likely involves increased cortisol clearance and reduced adrenal sensitivity to ACTH.

Non-modifiable suppressors

Primary adrenal insufficiency (Addison's disease) and hypopituitarism both produce very low DHEA-S. These diagnoses require full endocrine evaluation, not simply DHEA supplementation. A DHEA-S below 30 mcg/dL in an adult under 55 should prompt measurement of morning cortisol, ACTH stimulation testing, and referral to endocrinology.

DHEA-S as Part of a Comprehensive Longevity Panel

DHEA-S does not operate in isolation. Its clinical significance is best interpreted alongside the following biomarkers, which together build a picture of the patient's biological age and hormonal milieu.

Recommended companion biomarkers

• Total and free testosterone: DHEA-S is a direct precursor. Low testosterone with low DHEA-S points toward adrenal contribution to androgen deficiency, not just primary hypogonadism.
• Estradiol (E2): Particularly in postmenopausal women, where DHEA-S is a major source of peripheral estrogen production.
• Cortisol (AM): The cortisol-to-DHEA ratio is an emerging marker of biological stress and aging. A ratio above 10:1 (cortisol mcg/dL to DHEA mcg/dL) is associated with poorer outcomes in several aging studies.
• IGF-1: Growth hormone and DHEA decline in parallel and synergistically affect lean mass, bone density, and cognition. Treating one without assessing the other may produce incomplete responses.
• Fasting insulin and HOMA-IR: Insulin resistance is both a consequence and potential cause of low DHEA-S. Improving insulin sensitivity through dietary changes and exercise often raises DHEA-S modestly without supplementation.
• hsCRP: Low-grade inflammation suppresses adrenal androgen output. Reducing CRP through lifestyle modifications may partially restore DHEA-S.

A 65-year-old with DHEA-S of 90 mcg/dL, morning cortisol of 22 mcg/dL, fasting insulin of 18 uIU/mL, and hsCRP of 3.2 mg/L presents a very different clinical picture than one with the same DHEA-S but optimal metabolic markers. The first patient likely benefits more from insulin sensitization and cortisol management before DHEA supplementation is added.

Sex-Specific Considerations

Women: menopause and post-menopause

After natural menopause, the ovarian contribution to circulating androgens drops sharply. Adrenal DHEA-S becomes the dominant source of sex steroids in post-menopausal women, making it more clinically relevant than at any other life stage. The North American Menopause Society (NAMS) 2022 position statement acknowledges the role of DHEA in vulvovaginal health but notes that systemic evidence for mood, cognition, and cardiovascular benefits remains insufficient for a broad recommendation [13].

Women receiving estrogen-progestogen HRT should still have DHEA-S checked. HRT does not directly replace adrenal androgens. A woman on estradiol patches and progesterone may still have DHEA-S of 60 mcg/dL, representing a gap in her hormonal restoration that warrants consideration.

Men: interaction with TRT

Men on testosterone replacement therapy (TRT) receive exogenous testosterone, which may suppress endogenous LH and FSH but does not directly affect adrenal DHEA-S output. A man on 200 mg/week testosterone cypionate may have excellent total testosterone levels but DHEA-S of 85 mcg/dL. These are independent axes. Adding DHEA 25-50 mg/day in this setting may improve mood, cognitive clarity, and libido response that testosterone alone did not fully address, though controlled trial evidence for this additive effect is sparse.

Practical Testing and Timing Notes

DHEA-S can be drawn at any time of day because diurnal variation is less than 15%. Fasting is not required. A single measurement is usually sufficient for baseline assessment. Repeat testing after initiating supplementation should occur at 6-8 weeks (not sooner) to allow serum levels to stabilize.

Biotin (vitamin B7) supplements at doses above 5 mg/day can cause falsely elevated DHEA-S on immunoassay-based platforms due to biotin-streptavidin interference. Patients should stop biotin for at least 48 hours before the blood draw. This is a commonly missed pre-analytic error that produces spuriously reassuring results.

Liquid chromatography-tandem mass spectrometry (LC-MS/MS) assays are immune to biotin interference and are the gold-standard method when clinical accuracy is essential, such as when evaluating for adrenal tumors or congenital adrenal hyperplasia. Most standard commercial panels use immunoassay, which is adequate for monitoring but not for edge-case diagnostics.